AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $20,310,000 | -1.0% | 596,483 | -72.5% | 4.70% | -19.6% |
| Q2 2022 | $20,522,000 | -33.4% | 2,171,664 | 0.0% | 5.84% | -14.5% |
| Q1 2022 | $30,816,000 | -32.9% | 2,171,664 | 0.0% | 6.83% | -17.4% |
| Q4 2021 | $45,931,000 | -6.6% | 2,171,664 | -1.3% | 8.28% | +68.9% |
| Q3 2021 | $49,187,000 | -9.9% | 2,200,778 | 0.0% | 4.90% | -24.0% |
| Q2 2021 | $54,601,000 | -23.0% | 2,200,778 | -10.0% | 6.44% | -4.3% |
| Q1 2021 | $70,909,000 | +12.4% | 2,444,311 | 0.0% | 6.74% | +21.1% |
| Q4 2020 | $63,063,000 | -16.2% | 2,444,311 | 0.0% | 5.57% | -51.3% |
| Q3 2020 | $75,260,000 | -4.1% | 2,444,311 | -22.4% | 11.44% | -82.5% |
| Q2 2020 | $78,498,000 | +17.5% | 3,150,019 | 0.0% | 65.27% | +14.7% |
| Q1 2020 | $66,780,000 | -23.6% | 3,150,019 | -20.1% | 56.91% | +51.8% |
| Q4 2019 | $87,460,000 | -2.8% | 3,940,543 | -0.4% | 37.50% | -12.2% |
| Q3 2019 | $89,973,000 | +18.8% | 3,954,858 | 0.0% | 42.68% | +27.0% |
| Q2 2019 | $75,736,000 | – | 3,954,858 | – | 33.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |